Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The efficacy and safety of luspatercept in patients with low-blasts myelodysplastic neoplasms in real world

View Full Paper
Ask AI
Bookmark
Share

Authors

HJHuijuan JiangTianjin Medical University General HospitalHWH WangGuilin Medical UniversityYWYuhong WuGuangxi Medical University

Discussion

Loading...

Member takes

Overview

Observational study shows luspatercept improves anemia and response rates in low-blasts MDS, indicating favorable outcomes.

Key Points

  • To analyze the efficacy and safety of luspatercept in patients with low-blasts myelodysplastic neoplasms.
  • Enrolled patients newly diagnosed with low-blasts MDS in a hematology department.
  • Patients received luspatercept or erythropoiesis-stimulating agents as treatment.
  • Measured primary endpoint as proportion of patients achieving hematologic improvement in erythroid.
  • Monitored adverse events as per CTCAE 5.0 criteria.
  • Compared responses between treatment groups.
  • Luspatercept group showed a higher hematologic improvement rate (73.9% vs. 55%).
  • Median hemoglobin levels significantly increased after luspatercept treatment (P<0.05).
  • Median time to achieve response was shorter with luspatercept (1.5 vs. 5 months, P<0.01).
  • No serious adverse events observed in luspatercept group.

Cite This Study

Jiang et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e07chttps://doi.org/10.1182/blood-2025-7400
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa2024 · 7 citations
  2. 2Luspatercept for the treatment of myelodysplastic syndrome: A retrospective cohort study utilizing trinetx2025
  3. 3Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.2024 · 2 citations
  4. 4Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial2025 · 1 citations
  5. 5Luspatercept response predictors in lower-risk myelodysplastic syndrome2025